Abstract 3926
Background
The benefits of ICIs for patients (pts) with NSCLC have been shown in several clinical trials, but real-world data are limited. We describe the early impact of 2L ICI Tx on clinical practice at the Leeds Cancer Centre (LCC), a UK site of I-O Optimise, a multinational research platform providing insights into real-world lung cancer management.
Methods
This retrospective cohort study used longitudinal data from electronic medical records of adults diagnosed with advanced NSCLC (stage IIIB/IV) between Jan 2013 and Oct 2018 (2-month minimum follow-up). Pts with EGFR or ALK mutations were excluded from the analysis due to different Tx patterns expected in this population eligible for targeted Tx. Pre- and post-ICI sub-cohorts were defined by date of first 2L ICI use at LCC (Mar 2016). Distinct lines of Tx were identified using a clinically verified algorithm based on date of prescribed systemic anti-cancer therapy (SACT) and time between prescriptions. Age and ECOG performance score (PS) at time of initial diagnosis were recorded.
Results
Of 1196 pts with advanced NSCLC during the study period, 409 (34.2%) received SACT; (annual rates were 33.5–38.1%). In all, 103 pts (8.6%) received 2L Tx, of which 26 (25.2%) had EGFR/ALK mutations; of the remaining 77 pts without EGFR/ALK mutations, 29 were treated pre-ICI and 48 post-ICI. In the pre-ICI sub-cohort, median age was 65.0 yrs and 82.8% had an ECOG PS < 2; 13 pts (44.8%) received a tyrosine kinase inhibitor, 6 (20.7%) had non-platinum SACT, and most remaining pts had platinum SACT. All had platinum SACT as first-line (1L) Tx. In the post-ICI sub-cohort, median age was 67.0 yrs and 77.1% had an ECOG PS < 2; 26 pts (54.2%) received an ICI (pembrolizumab, nivolumab, or avelumab), 10 (20.8%) had platinum SACT, and 7 (14.6%) had non-platinum SACT. Almost all pts (89.6%) had platinum SACT as 1L Tx, with the rest receiving an ICI. Early outcomes and 2L duration in pre- and post-ICI sub-cohorts will be presented.
Conclusions
Two years on from the introduction of ICIs as a 2L option in UK clinical practice, their use is well established among eligible pts, but overall 2L SACT Tx remains very low. The impact on survival will be presented.
Clinical trial identification
Editorial acknowledgement
Richard Daniel, PhD and Kate Bradford, PhD of PAREXEL, funded by Bristol-Myers Squibb.
Legal entity responsible for the study
Bristol-Myers Squibb.
Funding
Bristol-Myers Squibb.
Disclosure
M. Snee: Research grant / Funding (institution), I am a paid consultant to IQVIA. My employer Leeds teaching hospitals NHS trust has received a grant from IQVIA: IQVIA. L. Lacoin: Advisory / Consultancy, Consultant for BMS: Bristol-Myers Squibb. W. Sopwith: Full / Part-time employment, I am employed by IQVIA to work on this project: IQVIA. C. Chaib: Full / Part-time employment, Employee: Bristol-Myers Squibb. J.R. Penrod: Shareholder / Stockholder / Stock options, Full / Part-time employment: Bristol-Myers Squibb. J.C. O’Donnell: Shareholder / Stockholder / Stock options, Full / Part-time employment: Bristol-Myers Squibb. All other authors have declared no conflicts of interest.
Resources from the same session
5011 - LCSCAF1 maintains cancer stem-like traits by stabilizing c-Myc protein and promotes metastasis and recurrence in lung cancer
Presenter: Tao Guo
Session: Poster Display session 1
Resources:
Abstract
4955 - XAF1 Enhances Temozolomide Induced Autophagic Cell Death through AMPK signaling pathway
Presenter: Mingoo Lee
Session: Poster Display session 1
Resources:
Abstract
5616 - The effect of cortisol on methylation patterns in breast cancer cell lines
Presenter: Haya Intabli
Session: Poster Display session 1
Resources:
Abstract
4649 - Global and sex-specific epigenome-wide association studies for the identification of the main methylated loci related to smoking in a Mediterranean population
Presenter: Judith Begona Ramirez Sabio
Session: Poster Display session 1
Resources:
Abstract
4984 - Whole transcriptomics analyses of mimicking Circulating Tumor Cells (CTCs) by single-cell RNA sequencing (scRNAseq)
Presenter: Jessica Garcia
Session: Poster Display session 1
Resources:
Abstract
5926 - Comparison of enzymatic- and bisulfite conversion to map the plasma cell-free methylome in cancer
Presenter: Nicole Lambert
Session: Poster Display session 1
Resources:
Abstract
5454 - Detection of low mutations in hepatocellular carcinoma by using circulating tumor DNA
Presenter: Esl Kim
Session: Poster Display session 1
Resources:
Abstract
4428 - Variants in the JAK1 and JAK2 genes in the risk and prognosis of patients with cutaneous melanoma
Presenter: Bruna Carvalho
Session: Poster Display session 1
Resources:
Abstract
4409 - P-Rex1 expression in breast cancer patients.
Presenter: Angela Lara Montero
Session: Poster Display session 1
Resources:
Abstract
4185 - Modulation of Risk of Cutaneous Melanoma Patients by Variants in STAT3 Gene and Functional Analysis
Presenter: Gabriela Gomez
Session: Poster Display session 1
Resources:
Abstract